Axcelead DDP and Knowledge Palette Enter into a Collaborative Research Contract on Gene Expression Analysis Concerning Drug-Resistant Cancer
Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; CEO: Yoshinori Ikeura) and Knowledge Palette, Inc. (headquarters: Kawasaki,...
Dr. Hideo Fukui will chair the international symposium about new modalities at the American College of Toxicology 2022 annual meeting.
The American College of Toxicology 2022 annual meeting will be held in Denver on November 13 to...
Axcelead Drug Discovery Partners and Acadia Pharmaceuticals Launch Drug Discovery Collaboration in Neuroscience
October 5, 2022 – Axcelead Drug Discovery Partners Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as...
Epigeneron and Axcelead DDP singed a master collaboration agreement on drug discovery research for novel drug targets
Epigeneron Inc., (Headquarters: Chuo-ku, Tokyo, President: Tetsuya Mishima, “Epigeneron”) and Axcelead Drug Discovery Partners, Inc. (Headquarters: Fujisawa City,...
Perseus Proteomics and Axcelead DDP launch a collaboration for an antibody drug discovery support service
Perseus Proteomics Inc. (Head office: Meguro, Tokyo; President & CEO: Takuya Yokokawa, “Perseus”) and Axcelead Drug Discovery...
ARCALIS and Axcelead DDP Announce Collaboration to Provide Integrated Drug Discovery Support Service for mRNA Therapeutics
TOKYO, JAPAN, 20 JULY 2022: ARCALIS Inc. (Head office: Kashiwa, Chiba; President & CEO: Tomoyuki Fujisawa; “ARCALIS”)...